Advertisement
A vs AZTA
Which Stock Would AI Choose? Agilent Technologies (A) vs. Azenta (AZTA) Stock Comparison
Key Takeaways
- Agilent Technologies (A) operates at a significantly larger scale with a market capitalization exceeding $40 billion, compared to Azenta’s (AZTA) approximately $1.6 billion.
- Both companies reported positive recent quarterly results, with Agilent raising full-year guidance after a strong earnings beat and Azenta returning to quarterly profitability while lifting revenue outlook.
- Agilent (A) stock has demonstrated stronger recent momentum, rising over 11% in the past month amid anticipation of its August 26 earnings release.
- Azenta (AZTA) completed a $50 million share repurchase program following its August 4 earnings report, signaling management confidence in its trajectory.
- Agilent (A) benefits from broader life sciences exposure and more consistent revenue growth, while Azenta (AZTA) focuses on specialized sample management and automation services.
- Market sentiment favors Agilent (A) for stability and visibility, though Azenta (AZTA) offers potential upside from operational improvements and capital returns.
Introduction
Agilent Technologies (A) and Azenta (AZTA) are both participants in the life sciences tools and services sector, making them relevant for comparison among investors seeking exposure to biotechnology and laboratory instrumentation markets. Traders and portfolio managers evaluating relative performance, sector positioning, and recent operational developments may find this analysis useful for assessing how these stocks have responded to earnings cycles and broader market conditions in recent weeks. The comparison highlights differences in scale, growth drivers, and momentum without implying specific investment outcomes.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides analytical instruments, software, and services primarily for life sciences, diagnostics, and applied chemical markets. In recent market activity, the stock has shown resilience, trading near $159 following gains of more than 11% over the past month. The company reported a second-quarter fiscal 2026 earnings beat with EPS of $1.49 versus analyst estimates of $1.41 and subsequently raised its full-year guidance. Sentiment has been supported by this performance and anticipation of third-quarter results scheduled for August 26, contributing to steady accumulation amid favorable sector trends.
Azenta (AZTA) Overview and Recent Performance
Azenta (AZTA) specializes in automated sample management, cold-chain logistics, and related services for the life sciences industry. Following its third-quarter fiscal 2026 earnings release on August 4, the company noted 9% organic revenue growth, a return to quarterly profitability, and an upward revision to full-year revenue guidance. The stock has traded around $37 in recent sessions, reflecting gains over the prior 90 days despite a more modest year-to-date performance. A completed $50 million share repurchase program has contributed to positive sentiment around capital allocation and operational execution.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots designed to navigate thousands of tickers across varying market conditions. While hundreds of AI Trading Bots are available with diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, only the strongest performers suited to prevailing environments are featured in the Trending AI Robots section. These bots can exhibit wide ranges in historical returns, win rates, and drawdown profiles depending on their parameters. Investors exploring algorithmic approaches may review the page for additional context on current trending options.
Head-to-Head Comparison
Agilent Technologies (A) and Azenta (AZTA) differ markedly in business scale and focus. Agilent operates a diversified portfolio of instrumentation and services with broader exposure to global life sciences research and diagnostics, supporting more predictable revenue streams. Azenta concentrates on niche automation and sample management solutions, which can deliver higher growth sensitivity to specific industry demand but may carry greater volatility. Recent momentum has favored Agilent (A) through earnings visibility and sector tailwinds, whereas Azenta (AZTA) has emphasized share repurchases and margin recovery. Risk factors include Agilent’s larger valuation multiples versus Azenta’s smaller capitalization and execution dependencies. Market sentiment reflects Agilent’s established positioning against Azenta’s potential for accelerated improvement.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative market positioning, Tickeron’s AI would currently assign a higher probability of favorable near-term performance to Agilent Technologies (A). The larger capitalization, raised guidance, and upcoming catalyst provide a more established foundation compared with Azenta’s (AZTA) recovery trajectory, though outcomes remain subject to broader market dynamics and execution results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and AZTA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileAZTA’s FA Score has 0 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- AZTA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while AZTA’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 5 bearish.
- AZTA’s TA Score: 4 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -1.94% price change this week, while AZTA (@Pharmaceuticals: Other) price change was -4.92% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +5.68%. For the same industry, the average monthly price growth was +11.00%, and the average quarterly price growth was +34.25%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.63%. For the same industry, the average monthly price growth was +1.98%, and the average quarterly price growth was +11.27%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
AZTA is expected to report earnings on Nov 17, 2026.
Industries' Descriptions
@Medical Specialties (+5.68% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-0.63% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| A | AZTA | A / AZTA | |
| Capitalization | 42.5B | 1.37B | 3,095% |
| EBITDA | 2.04B | 32.9M | 6,185% |
| Gain YTD | 11.535 | -5.803 | -199% |
| P/E Ratio | 29.76 | 42.43 | 70% |
| Revenue | 7.37B | 614M | 1,201% |
| Total Cash | 1.76B | 326M | 539% |
| Total Debt | 3.95B | 54M | 7,313% |
A | AZTA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 95 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 45 | 93 | |
PRICE GROWTH RATING 1..100 | 22 | 42 | |
P/E GROWTH RATING 1..100 | 43 | 86 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (11) in the Biotechnology industry is in the same range as AZTA (41) in the Electronic Production Equipment industry. This means that A’s stock grew similarly to AZTA’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AZTA (100) in the Electronic Production Equipment industry. This means that A’s stock grew similarly to AZTA’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for AZTA (93) in the Electronic Production Equipment industry. This means that A’s stock grew somewhat faster than AZTA’s over the last 12 months.
A's Price Growth Rating (22) in the Biotechnology industry is in the same range as AZTA (42) in the Electronic Production Equipment industry. This means that A’s stock grew similarly to AZTA’s over the last 12 months.
A's P/E Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for AZTA (86) in the Electronic Production Equipment industry. This means that A’s stock grew somewhat faster than AZTA’s over the last 12 months.
| A | AZTA | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 58% | 4 days ago 78% |
| Stochastic ODDS (%) | 4 days ago 61% | 4 days ago 73% |
| Momentum ODDS (%) | 4 days ago 56% | 4 days ago 73% |
| MACD ODDS (%) | 4 days ago 51% | 4 days ago 80% |
| TrendWeek ODDS (%) | 4 days ago 63% | 4 days ago 79% |
| TrendMonth ODDS (%) | 4 days ago 60% | 4 days ago 82% |
| Advances ODDS (%) | 12 days ago 60% | 12 days ago 72% |
| Declines ODDS (%) | 7 days ago 63% | 7 days ago 81% |
| BollingerBands ODDS (%) | 4 days ago 71% | 4 days ago 69% |
| Aroon ODDS (%) | 4 days ago 64% | 4 days ago 80% |
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
AZTA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with IQV. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To AZTA | 1D Price Change % | ||
|---|---|---|---|---|
| AZTA | 100% | +0.48% | ||
| IQV - AZTA | 60% Loosely correlated | -1.42% | ||
| RVTY - AZTA | 59% Loosely correlated | -0.31% | ||
| A - AZTA | 59% Loosely correlated | +0.59% | ||
| MTD - AZTA | 59% Loosely correlated | -0.81% | ||
| BRKR - AZTA | 58% Loosely correlated | -1.53% | ||
More | ||||